Free Trial
Rudy Li

Rudy Li Analyst Performance

Biotechnology Analyst at Chardan Capital

Rudy Li is a stock analyst at Chardan Capital in the medical sector, covering 7 publicly traded companies. Over the past year, Rudy Li has issued 12 stock ratings, including and buy recommendations. While full access to Rudy Li's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Rudy Li's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
13 Last 2 Years
Buy Recommendations
100.00% 13 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%13 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
7 companies

Rudy Li, an analyst at Chardan Capital, currently covers 7 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Rudy Li of Chardan Capital specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
85.7%
MED - DRUGS
1 company
14.3%

About Rudy Li

Rudy Li, PhD, CFA is on Chardan's equity research team focusing on CNS-related companies. He has over six years of experience in biotech equity research and healthcare investment banking. Prior to joining Chardan, Rudy was an equity research analyst at Leerink Partners, covering SMID cap biotech companies across multiple therapeutic areas with a specialization in neuroscience. Rudy earned a Ph.D. in Chemistry from Stony Brook University, and a B.S. in Chemistry from Jilin University.
Follow on LinkedIn

Rudy Li's Ratings History at Chardan Capital

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Prothena Corporation plc stock logo
PRTA
Prothena
8/28/2025Reiterated Rating$8.56$18.00Buy
Stoke Therapeutics, Inc. stock logo
STOK
Stoke Therapeutics
8/13/2025Reiterated Rating$16.44$24.00Buy
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
8/12/2025Reiterated Rating$35.99$55.00Buy
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
8/12/2025Reiterated Rating$17.11$30.00Buy
Prothena Corporation plc stock logo
PRTA
Prothena
8/5/2025Reiterated Rating$6.94$18.00Buy
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
8/1/2025Reiterated Rating$9.09$20.00Buy
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
7/30/2025Reiterated Rating$16.56$30.00Buy
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
7/29/2025Reiterated Rating$55.65$80.00Buy
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
5/8/2025Initiated Coverage$12.08$30.00Buy
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
5/7/2025Initiated Coverage$35.18$55.00Buy
Praxis Precision Medicines, Inc. stock logo
PRAX
Praxis Precision Medicines
5/7/2025Initiated Coverage$35.17$80.00Buy
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
5/7/2025Initiated Coverage$29.40$80.00Buy